title: Relationship between early pregnancy factor, mouse embryo-conditioned medium and platelet-activating factor.
abstract: The effects of synthetic platelet-activating factor (PAF-acether) and mouse embryo-conditioned medium (a source of embryo-derived PAF (EPAF)) on production of early pregnancy factor (EPF) were compared. Embryo-conditioned medium, itself inactive in the EPF bioassay, stimulated ovarian production of EPF in vitro but PAF-acether did not. In vivo, embryo-conditioned medium induced EPF activity in serum of oestrous female, but not in male, mice in contrast to PAF-acether, which induced activity in serum of both male and female mice. This PAF-induced activity was transitory, declining significantly by 2 h and disappearing by 3 h after injection. Activity induced by embryo-conditioned medium was first evident at 2 h after injection, serum concentrations increasing up to 6 h after injection. By discriminating between the behaviour of PAF-acether and EPAF, these studies reinforce the conclusions of other workers that the molecule produced by the embryo is not PAF. Further investigations into the mechanism of action of PAF-acether revealed that it is a potent inducer of activity in the EPF bioassay, with an absolute requirement for platelets in the spleen cell suspension used in the assay. This platelet-derived active species was bound specifically by an anti-EPF monoclonal antibody, indicating that it is EPF-like. This is consistent with parallel studies showing that platelets are not required for induction of activity by either pregnancy serum or purified EPF. These studies were applied to the PAF-induced leukotriene-like species, which had been found by others to be active in the EPF bioassay. Pregnancy serum induced the appearance of this substance from the spleen cell suspension used in the assay; thus the leukotriene-like substance may be regarded as an effector molecule in vitro or mediator of the initiating stimulus of EPF in the bioassay.
authors.affiliation: Department of Surgery, University of Queensland, Royal Brisbane Hospital, Australia.
authors.forename: A C
authors.initials: AC
authors.lastname: Cavanagh
authors.forename: B E
authors.initials: BE
authors.lastname: Rolfe
authors.forename: S
authors.initials: S
authors.lastname: Athanasas-Platsis
authors.forename: K A
authors.initials: KA
authors.lastname: Quinn
authors.forename: H
authors.initials: H
authors.lastname: Morton
mesh_terms: D000818:Animals; D001681:Biological Assay / Q000379:methods; D002478:Cells, Cultured; D018835:Chaperonin 10; D003470:Culture Media; D004622:Embryo, Mammalian / Q000378:metabolism*; D005260:Female; D007163:Immunosorbent Techniques; D015289:Leukotrienes / Q000378:metabolism; D008297:Male; D051379:Mice; D010053:Ovary / Q000187:drug effects / Q000378:metabolism*; D010452:Peptide Biosynthesis; D010455:Peptides; D010972:Platelet Activating Factor / Q000494:pharmacology*; D011247:Pregnancy; D011257:Pregnancy Proteins; D013154:Spleen / Q000166:cytology; D013491:Suppressor Factors, Immunologic; D013997:Time Factors
chemical_list: D018835:Chaperonin 10; D003470:Culture Media; D015289:Leukotrienes; D010455:Peptides; D010972:Platelet Activating Factor; D011257:Pregnancy Proteins; D013491:Suppressor Factors, Immunologic; C025124:early pregnancy factor